Stock AnalizVor Biopharma Inc. VOR
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Vor Biopharma Inc. (VOR) is a healthcare company listed in the US with a market value of about $1.2B.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.1, a 5-year average ROIC of -44%.
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$696M | -$117M | -$118M | -$92M | -$69M | -$43M |
| Free cash flow | -$144M | -$100M | -$101M | -$94M | -$73M | -$40M |
| EPS (diluted) | $-11.75 | $-5.67 | $-5.83 | $-7.77 | $-7.00 | $-768.51 |
| Net margin | — | — | — | — | — | — |
| ROIC | — | -74.5% | -53.4% | -25.5% | -23.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $39.00, 101% above the current price; targets range from $27.00 to $50.00; the consensus rating is “Strong buy”; expected EPS is $-6.67 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Vor Biopharma’s P/E ratio?
About 0.1, based on the last twelve months of diluted earnings per share.
Does Vor Biopharma pay a dividend?
Not currently.
Is Vor Biopharma a good stock to buy?
We do not give buy or sell advice. Vor Biopharma scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.